Can hypertonic saline 2% be administered through a peripheral intravenous line?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can 2% Hypertonic Saline Be Given Through a Peripheral Line?

Yes, 2% hypertonic saline can be safely administered through a peripheral intravenous line. The evidence demonstrates that even 3% hypertonic saline—which is more concentrated than 2%—has been shown to be safe via peripheral access with low complication rates.

Evidence Supporting Peripheral Administration

The most recent and robust evidence comes from multiple studies examining 3% HTS through peripheral lines:

  • A 2023 systematic review and meta-analysis of 1,200 patients receiving peripheral 3% HTS showed remarkably low complication rates: infiltration 3.3%, phlebitis 6.2%, erythema 2.3%, edema 1.8%, and venous thrombosis 1% 1

  • A 2023 retrospective study of rapid bolus administration (≥250 mL/h, up to 999 mL/h) of 3% HTS peripherally in neurologic emergencies found zero episodes of extravasation or phlebitis 2

  • A 2022 pediatric study of 1,020 administrations through peripheral IV showed only 0.9% infiltration rate with bolus dosing and 7.6% with continuous infusion, with no extravasations or long-term morbidity 3

Practical Considerations

Since 2% HTS has lower osmolarity (approximately 684 mOsmol/L) compared to 3% HTS (1026 mOsmol/L) 4, it poses even less risk to peripheral veins.

Administration Guidelines:

  • Preferred IV gauge: 18-20 gauge in antecubital or other large peripheral veins 2
  • Infusion rates: Studies show safety up to 999 mL/h for bolus administration 2, though rates of 30-75 mL/h are commonly used for continuous infusions 5
  • Monitoring: Assess IV site hourly for signs of infiltration, erythema, or swelling 5
  • Serum sodium monitoring: Check within 6 hours of administration; do not re-administer until serum sodium <155 mmol/L 4

Key Caveats:

  • Continuous infusions carry higher infiltration risk (7.6%) compared to bolus administration (0.9%) 3
  • Central access may still be preferred for prolonged infusions (>48-72 hours) or when peripheral access is poor
  • The traditional concern about peripheral administration of hypertonic solutions appears to be overstated and unfounded based on current evidence 5

Clinical Bottom Line

2% hypertonic saline is safe for peripheral administration and actually carries less risk than the well-studied 3% concentration. The evidence consistently shows that complications are rare, minor, and non-life-threatening when they do occur 1, 5. This is far safer than the potential complications of central line placement (pneumothorax, arterial injury, large vessel thrombosis, bloodstream infection) 5.

Ensure proper IV gauge (18-20), monitor the site regularly, and track serum sodium levels appropriately 2, 6.

References

Research

Peripheral IV Administration of Hypertonic Saline: Single-Center Retrospective PICU Study.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2022

Research

Complication Rates of 3% Hypertonic Saline Infusion Through Peripheral Intravenous Access.

The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2017

Research

Hypertonic saline use in neurocritical care for treating cerebral edema: A review of optimal formulation, dosing, safety, administration and storage.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.